Sponsor: SWOG
Sponsor Study ID: S1900G
Study Title: A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
CTO #: 103915
NCT Number: NCT05642572
Phase: II
Protocol Type: Treatment
Age Group: Unspecified
Disease Sites: Lung
Study Objectives: The primary objective is to compare investigator-assessed progression-free survival (IAPFS) between participants with EGFR mutated, MET amplified NSCLC randomized to INC280 (capmatinib) and osimertinib with or without ramucirumab